DPP4 and type 2 diabetes mellitus: The SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial was a large, multinational, randomized study that aimed to assess the cardiovascular safety of saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes mellitus who were at high risk for cardiovascular events.